再生元制药公司 REGN 深 沪
已收盘 11-06 16:00:00 美东时间
904.35
+1.450
+0.16%
华盛通- 最 高911.64
- 今 开887.22
- 成交量 112.29万股
- 最 低 887.04
- 昨 收 902.90
- 总市值 935.53亿
- 52周最高 991.73
- 市盈率 静 21.80
- 换手率 1.09%
- 52周最低 590.58
- 委 比 -4.15%
- 总股本 1.03亿
- 历史最高 1204.8599
- 量 比 0.66
- 振 幅 2.72%
- 历史最低 36.49
- 每 手 1
- 风险率 66.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多QFRD前十大重仓股占比32.0474%，第一大重仓股为再生元制药
数据显示，QFRD前十大重仓股合计占基金资产的32.0474%。 其中，第一大重仓股为再生元制药，持仓占比3.9412%；第二大重仓股为因塞特医疗，占比3.7...
11-07 07:15
内部人交易｜再生元制药披露一笔股票减持，金额约98.42万美元
美股上市公司再生元制药（REGN）披露一笔内部人股票交易。文件显示，公司内部人McCourt (Marion E)（Officer）2026-10-30减持公司...
11-06 07:03
Regeneron Advances ALN-CIDEB Into Phase 3 Liver Disease Study
Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical...
11-06 00:33
Regeneron and Sanofi Update Long-Term Pediatric Dupixent Study
Regeneron Pharmaceuticals ($REGN), Sanofi ($SNYNF) announced an update on their...
11-04 00:30
美股大行评级 | 潜在涨幅2250.23%！艾伯维获大摩等多家大行上调目标价，最高340美元
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从50美元升至51美元；HC Wainwright & Co.：上调伊诺维奥制药评级至"买入"，目标价5美元
11-03 18:20
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations
Intellia Therapeutics will present new clinical data on nex-z, a CRISPR-based treatment for transthyretin amyloidosis, at two medical meetings in November. At the American Heart Association (AHA) Scientific Sessions 2026, cardiac outcomes from a single dose of nex-z in patients with mixed phenotype ATTRv-PN will be highlighted. At the International Society of Amyloidosis (ISA) 2026 Symposium, long-term follow-up data from the Phase 1 trial in ATT...
11-03 13:00
再生元制药收涨3.6%，成交额15.93亿美元
11月3日，再生元制药（REGN）收涨3.6%，报961.26美元，成交额15.93亿美元，市值989.67亿美元。 行情数据 • 开盘价：927.22美元 ...
11-03 05:33
Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter
As of Nov. 2, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices g...
11-02 21:45
Regeneron Announces Investor Conference Presentations
Regeneron Pharmaceuticals will participate in three healthcare conferences in 2026: the Jefferies Global Healthcare Conference on November 17, the Evercore Healthcare Conference on December 1, and Citi’s Global Healthcare Conference on December 2. Details and replays can be accessed via Regeneron's website. The company, known for developing life-transforming medicines, uses proprietary technologies like VelociSuite to advance treatments for vario...
11-02 21:05
Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer
Syndax Pharmaceuticals announced the retirement of CFO Keith A. Goldan and the appointment of Aaron A. Ondrey as the new CFO. Goldan, who played a key role in the successful launches of Revuforj and Niktimvo, will remain with the company through year-end to support the transition. Ondrey brings over 25 years of financial and operational leadership experience in the biotechnology industry.
11-02 21:01
